Efficacy evaluation of antifungal therapy in GM-positive bronchial charcoal fibrosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048461

Enrollment

Unknown

Registered

2021-07-09

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial anthracofibrosis (BAF)

Interventions

Experimental group:oral itraconazole

Control group:oral placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Electronic bronchoscopy clearly diagnosed patients with BAF, and the GM test was greater than 0.5S/CO.

Exclusion criteria

Exclusion criteria: 1. Combined with moderate to severe chronic obstructive pulmonary disease; 2. Those who use semi-synthetic penicillin after admission; 3. Those who use high-dose hormone therapy; 4. Combined with severe liver and kidney insufficiency.

Design outcomes

Primary

Measure	Time frame
number of acute attacks;	—

Countries

China

Contacts

Public ContactZhou Guoqi

People's Hospital of Honghuagang District, Zunyi

31343639@qq.com+86 13017400789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026